207_Combined course Presentations

Economics and logistics of personalized medicine trials

• Each center needs to open multiple studies to be economically viable • Greater regulatory burden (protocols emendments, SUSARs) • Cost per case increased • Limited experience accumulated per centre • Collection of trial data by sponsor with sharing of toxicity data by grade and frequency on a regular basis throught protocol conduct